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mena, and haematological, renal, and liver function tests showed no abnormalities ascribable to chlormethiazole. Discussion Chlormethiazole proved a useful adjunct to the standard drug treatment in seven out of the nine episodes of status epilepticus in this study. The patients were highly selected in that they remained refractory to diazepam in adequate doses and three had failed to respond to intravenous thiopentone.
The value of intravenous diazepam in the immediate management of status epilepticus is well established.5 6 Its failure in some patients is probably due to inadequately maintained blood levels7 and is best overcome by the use of a continuous intravenous infusion. There remains, however, a small group of "refractory" patients.5 In these cases it had previously been our practice to give intravenous thiopentone as the drug of second choice. In subanaesthetic doses it can produce profound respiratory depression8 and in our experience the patient often needs assisted ventilation. Thus an effective alternative to diazepam is needed which is less apt than thiopentone to cause respiratory depression.
There are several reports of the efficacy of intravenous chlormethiazole in status epilepticus. 9-12 In all except one doses of between 1-2 g and 3 g were given as a bolus and repeated at intervals of up to four hours. The reports are uniformly enthusiastic about the results, but varying degrees of depression of the level of consciousness and respiration were encountered. Houdart and Laborit 11 used a similar regimen to ours (03 g/h as a constant infusion) and their patients did not have these side effects. More recently Manhire and Espir" described a case of status epilepticus in which chlormethiazole controlled the fits but only at a rate of infusion (1-5 g/h) which resulted in coma. '4 We obtained satisfactory results with a rate of infusion of 0-5-0 7 g/h without serious impairment of consciousness or de Leukaemia and Cot Deaths in 1 to 6-month-old Children Though leukaemia mortality rates have always been higher for boys than girls and have never shown any signs of being influenced by seasonal factors6 this was not true of leukaemia deaths in children aged 1-5 months (table I). In this age group, which accounts for less than 3% of childhood leukaemias, there were more girls than boys who died of leukaemia; more summer than winter deaths; and over twice as many deaths among January to June births than among July to December births. The last finding was of key importance because babies who are born in the second half of the year are intensively exposed to winter conditions between 1 and 6 months of age and so are more likely to die from respiratory infections in their first six months than January to June births (see table II). (table IV) . The small proportions of male cases of leukaemia and winter deaths from leukaemia in the exceptional age group (1-5 months) were preceded and followed by "normal" proportions (table I), and by 3 months of age an exceptionally high ratio of myeloid to lymphatic leukaemias had been replaced by the low ratio which is typical of childhood but not of adult leukaemias. 916  1366  145  292  2719  213  73  7  46  339  440  474  Expected  213  317  7  625  1162 Discussion During infancy two things happen which may explain why a childhood peak of lymphatic leukaemia mortality is not preceded by a peak incidence of non-specific and myeloid leukaemias. The level of immunological competence becomes less dependent on maternal factors (passive immunity) and more dependent on the child's own immune system (active immunity), and there is a wave of sudden deaths of apparently healthy babies which barely affects the neonatal period but has passed its peak by 4 months of age. The risk of dying from leukaemia is the same during both halves of infancy, but in the age group most affected by the sudden death hazard (1-5 months) there are fewer male cases and winter deaths. Also an initially high ratio of myeloid to lymphatic leukaemias is suddenly replaced by a low ratio, which persists until the end of childhood and is then replaced by a moderately high ratio.
We do not know how often difficulty in replacing passive with active immunity is the underlying cause of deaths which have respiratory factors as terminal causes. Nor do we know how often (if at all) immune deficiencies are caused by in-utero replacement of leucocyte stem cells with mutant cells. On the other hand, loss of immunological competence is an early consequence of leukaemia,' childhood leukaemias have fetal origins,4 and myeloid leukaemias have relatively short latent periods.8 Therefore the youngest batch of lymphatic leukaemias (which was barely detectable before antibiotics were discovered) could be preceded by a larger group of non-specific and myeloid leukaemias in which the proportion of unrecognized cases is exceptionally high because recognition depends on the whole of the latent period being spent in an infection-free environment. In Britain this condition is unlikely to be met by babies who are born in the second half of the year because they are intensively exposed to winter conditions from 1 to 5 months of age. Since this is the age group most affected by deaths which are due to difficulty in replacing passive with active immunity a likely alternative to a leukaemia death is a death from infection which is not recognized as such because there were none of the usual reactions to foreign proteins.
Therefore in infants aged 1-5 months a small proportion of July to December births among those dying from leukaemia might indicate that only a small proportion of infant leukaemias are being recognized; and a large proportion of July to December births among cot deaths might indicate that terminal causes of death in cases of infant leukaemias are no easier to recognize than underlying causes.
The conclusion that infant leukaemias cause some sudden deaths of apparently healthy babies invites comparisons between actual numbers of stillbirths and cot deaths and estimated numbers of children with leukaemia affected by the sudden death hazard. The provisional estimates in table V are based on three assumptions.
(1) Myeloid and lymphatic leukaemias together have the same frequency among adults and children with leukaemia, but there is better recognition of adults with myeloid leukaemia than children. Therefore the observed myeloid :lymphatic ratio for adult cases is the expected ratio for childhood cases (1.49). (2) The hazard of sudden death affects the youngest batch of children with non-specific leukaemias as much, or more than, the youngest group of children with cell-specific leukaemias. Therefore the expected ratio of nonspecific to myeloid cases among childhood leukaemias is the observed ratio for infant leukaemias (1.97, table I). ( 3) The only cell-specific cases affected by the sudden death hazard are myeloid leukaemias. Therefore the expected number of lymphatic and monocytic cases among childhood leukaemias is the observed number.
The observed numbers in table V6 show that from in England and Wales the yearly number of childhood deaths ascribed to leukaemia (339) was smaller than the yearly number of unexplained stillbirths (440) or the number of cot deaths in 1972 (474). But the difference between the observed and expected numbers of childhood leukaemias (823) was slightly smaller than the total number of unexplained deaths of apparently healthy babies (914).
